Onkolojide Güncel FAPİ PET BT Kullanımı
Synopsis
Fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) has emerged as a promising molecular imaging modality in oncology, offering a novel approach to tumor visualization by targeting cancer-associated fibroblasts (CAFs) within the tumor microenvironment. Unlike conventional fluorodeoxyglucose (FDG) PET/CT, which primarily reflects glucose metabolism, FAPI PET/CT targets fibroblast activation protein (FAP)—a protein overexpressed in the stromal compartment of many solid malignancies. This distinct biological mechanism can provide high tumor-to-background contrast, particularly in tumors characterized by extensive desmoplastic stroma, thereby improving the visualization of primary lesions, lymph node involvement, and distant metastases. This chapter examines the biological rationale underlying FAPI-based imaging, the development of relevant radiopharmaceuticals, and the current clinical applications of FAPI PET/CT across various cancer types, including pancreatic, gastric, colorectal, breast, lung, ovarian, and hepatobiliary cancers. Particular emphasis is placed on its potential role in initial staging, the detection of recurrent disease, the assessment of metastatic spread, and radiotherapy planning. The advantages of FAPI PET/CT over FDG PET/CT are discussed, alongside its limitations—such as variable uptake patterns, potential uptake in benign fibroblast activation, and the current lack of standardized acquisition and interpretation protocols. Furthermore, the emerging role of FAP-targeted radiopharmaceuticals in therapeutic strategies is explored. Although preclinical evidence is encouraging, the routine integration of FAPI PET/CT into oncological practice requires further validation through prospective, multicenter studies and direct comparisons with established imaging modalities. Future research should focus on defining tumor-specific indications, standardizing imaging protocols, and determining the impact of FAPI-guided management on clinical outcomes. By complementing conventional imaging and enhancing individualized cancer management, FAPI PET/CT represents a promising contribution to precision oncology.
References
Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev 2020;39(3):783–803.
Dendl K, Koerber SA, Kratochwil C, et al. FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers (Basel) 2021;13(19):4946.
Loktev A, Lindner T, Mier W, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med 2018;59(9):1423–1429.
Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review). Mol Med Rep 2015;11(5):3203–3211.
Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 2018;59(9):1415–1422.
Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med 2019;60(3):386–392.
Loktev A, Lindner T, Burger EM, et al. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. J Nucl Med 2019;60(10):1421–1429.
Millul J, Bassi G, Mock J, et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci U S A 2021;118(16):e2101852118.
Backhaus P, Gierse F, Burg MC, et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging 2022;49(6):1822–1832.
Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med 2021;62(2):201–207.
Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med 2019;60(6):801–805.
Ballal S, Yadav MP, Moon ES, et al. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2. Pharmaceuticals (Basel) 2021;14(12):1212.
EANM/SNMMI Practice Guideline for FAP-Targeted PET Imaging. Joint Consensus Statement and Procedural Recommendations. Eur J Nucl Med Mol Imaging / J Nucl Med 2025.
Meta-Analysis Group on Gastric Cancer. Diagnostic performance of 68Ga-FAPI PET/CT versus 18F-FDG PET/CT in gastric cancer: A systematic review and meta-analysis. Theranostics 2023;13(13):4694–4710.
Zhao L, Pang Y, Luo Z, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 2021;48(6):1944–1955.
Phulia RK, et al. Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Imaging: Diagnostic Applications, Comparison with FDG, Pitfalls, and Future Directions. Diagnostics 2023;13(12):2018.
Kuten J, Levine C, Shamni O, et al. Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging 2022;49(2):743–750.
Pang Y, Zhao L, Shang Q, et al. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2022;49(4):1322–1337.
Röhrich M, Naumann P, Giesel FL, et al. Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. J Nucl Med 2021;62(6):779–786.
Röhrich M, Loktev A, Wefers AK, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging 2019;46(12):2569–2580.
Koerber SA, Finck R, Dendl K, et al. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT. Eur J Nucl Med Mol Imaging 2021;48(12):3918–3924.
Gu B, Xu X, Zhang J, et al. The Added Value of 68Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG-Negative Findings. J Nucl Med 2022;63(6):875–881.
Elboga U, Sahin E, Cayirli YB, et al. Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience. Tomography 2022;8(1):293–302.
Varasteh Z, Mohanta S, Robu S, et al. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04. J Nucl Med 2019;60(12):1743–1749.
Zhao L, Chen S, Chen S, et al. 68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol 2021;158:55–61.
Windisch P, Röhrich M, Regnery S, et al. Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol 2020;150:159–163.
Liermann J, Syed M, Ben-Josef E, et al. Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer. Cancers (Basel) 2021;13(4):796.
Mori Y, et al. FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. RadioGraphics 2023;43(1):e220102.
Kratochwil C, Giesel FL, Rathke H, et al. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging 2021;48(9):3011–3013.
Watabe T, Liu Y, Kaneda-Nakashima K, et al. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. J Nucl Med 2020;61(4):563–569.
Sun L, Lin Q, Chen H, et al. State-of-the-art FAPI-PET imaging for cancer diagnosis and therapy. Theranostics 2022;12(4):1557–1570.
Sophie C Siegmund , Emil Novruzov , Eduards Mamlins , Yuriko Mori, Sven Otto , Martin Canis , Tadashi Watabe , Richard P Baum, Rudolf A Werner, Frederik L Giesel, Current status of FAP therapy in solid tumors, Review Semin Nucl Med. 2026 Jan;56(1):40-52